Social News
Written by: Kong Fanxu
2021-01-25 17:56
The last update date: 2021-01-25 17:56
The new crown pneumonia epidemic is raging in Hong Kong. The Secretary for Food and Health today (25th) approved Fosun Pharma/German pharmaceutical company BioNTech's new crown disease amaranth (ie, Comirnaty COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection) for emergency use in Hong Kong.
The production process of the first batch of about 1 million doses of vaccine prepared by Fosun Pharma/German pharmaceutical company BioNTech for Hong Kong has been completed and is expected to be shipped from Germany to Hong Kong in late February.
The government will start the territory-wide vaccination plan led by the government as soon as possible after receiving the relevant vaccines and completing the necessary quality inspection procedures.
▼Protection rate side effects of Kexing, BioNTECH Fosun, AstraZeneca ▼
+2
+2
+2
01News
The 3rd report of Kexing Vaccine has not been released
New crown vaccine | Norwegian elder dies after injection, WHO says it has nothing to do with Xu Shuchang, no need to panic
Anti-epidemic for one year | The Hospital Authority sets up seven vaccine centers, but it is difficult for hospitalized patients to receive injections
New Crown Vaccine | Survey: 78% of doctors and nurses are willing to inject six adults choose Kexing inactivated vaccine
Kexing Vaccine Report has no shadow. The government may choose 6 more inactivated vaccines for the Phase III study, including Sinopharm
New Coronary Pneumonia | Chen Zhaoshi Denies Concession to the Medical Care Strike to Negotiate the Purchase of the Fourth Vaccine Non-Chinese Medicine Development
If Kexing Vaccine has not submitted the data to the Hong Kong government or finds other Zeng Haohui materials, 2,000 people will be vaccinated per district per day
New Crown Vaccine︱The Committee of the Department of Health recommends that the residents and staff of the homes be given priority
New crown pneumonia vaccine
